These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16670899)

  • 1. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Niemi M; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jul; 62(7):503-9. PubMed ID: 16670899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
    Karonen T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2011 Feb; 67(2):151-5. PubMed ID: 20931329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
    Hegazy SK; Mabrouk MM; Elsisi AE; Mansour NO
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1275-80. PubMed ID: 22392555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone.
    Itkonen MK; Tornio A; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Drug Metab Dispos; 2016 Aug; 44(8):1364-71. PubMed ID: 27260150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
    Kim KA; Park PW; Kim KR; Park JY
    Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rifampicin on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
    Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H; Wu JT; Palmer R; McLean L
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.
    Aquilante CL; Wempe MF; Spencer SH; Kosmiski LA; Predhomme JA; Sidhom MS
    Pharmacotherapy; 2013 Sep; 33(9):1000-7. PubMed ID: 23712614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers.
    Kadam R; Bourne D; Kompella U; Aquilante C
    Biol Pharm Bull; 2013; 36(2):245-51. PubMed ID: 23370354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of human cytochrome P4502C8 by montelukast.
    Walsky RL; Obach RS; Gaman EA; Gleeson JP; Proctor WR
    Drug Metab Dispos; 2005 Mar; 33(3):413-8. PubMed ID: 15608135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.
    Karonen T; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
    Itkonen MK; Tornio A; Filppula AM; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2018 Sep; 104(3):495-504. PubMed ID: 29171020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.